BridgeMD
MOVE-JIA trial
EU CTIS ID: 2024-513017-12-00
What this study is testing
To assess the effect of two different treatment withdrawal strategies, compared to stable dose of methotrexate and tumor necrosis factor inhibitor (TNFi), on the risk of flares in children and adolescents with juvenile idiopathic arthritis in sustained inactive disease . Sustained inactive disease is defined as clinically judged inactive disease by treating physician at all appointments at least 12 months prior to inclusion AND inactive disease (Wallace) at inclusion to the study.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Fulfilment of the ILAR classification criteria for non-systemic JIA; 2 to <18 years of age at the time of signing the informed consent; sustained clinical remission for ≥12 months documented at a minimum of 2 visits during the last 18 months and Wallace inactive disease at inclusion; no active uveitis for ≥24 months; stable treatment with TNF-inhibitor and methotrexate for ≥3 months.
You likely can't join if
- Corticosteroid use (including intra-articular injections) at the indication of JIA less than 6 months prior to randomization; chronic widespread pain syndrome.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.